Stage 3A lung cancer means the cancer has grown beyond the lung itself and reached nearby lymph nodes on the same side of the chest, but has not spread to distant organs. It falls in the middle of the staging spectrum: more advanced than stages 1 or 2, but not yet considered stage 4 (metastatic). The five-year relative survival rate for regional-stage non-small cell lung cancer, which includes stage 3A, is around 40% based on data from people diagnosed between 2015 and 2021. That number has been improving as newer treatments become available.
What Stage 3A Means in Practical Terms
Lung cancer staging describes how far the disease has traveled from where it started. Stage 3A covers a range of scenarios that all share one common thread: the cancer has spread to lymph nodes near the center of the chest (around the windpipe, the aorta, or where the windpipe branches into the lungs), but only on the same side as the original tumor. It has not crossed to the opposite side of the chest or reached distant parts of the body like the brain, bones, or liver.
Within that framework, stage 3A includes several combinations of tumor size and local spread:
- Smaller tumors (5 cm or less) that have reached lymph nodes near the windpipe or aorta. The tumor may also extend into the main airway, the lining of the lung, or may have caused part of the lung to collapse.
- Mid-sized tumors (5 to 7 cm) that have spread to lymph nodes inside the lung or near the airway. There may be additional tumor nodules in the same lobe, or the cancer may have grown into the chest wall, the lining of the chest cavity, or the nerve that controls the diaphragm.
- Larger tumors (over 7 cm) or tumors invading critical structures like the windpipe, esophagus, heart, major blood vessels, breastbone, backbone, or the nerve controlling the voice box. These qualify as 3A when lymph node spread remains limited to the same side of the chest.
This range is important because two people with stage 3A diagnoses can have very different treatment paths. A person with a small tumor and limited lymph node involvement may be a candidate for surgery, while someone whose tumor wraps around a major blood vessel may not be.
Common Symptoms
By stage 3A, most people experience noticeable symptoms, though some are diagnosed after imaging for an unrelated issue. The most common signs include a persistent cough that worsens over time or produces bloody phlegm, shortness of breath, and chest pain. Because the cancer can press on or invade nearby structures, some people develop hoarseness (from pressure on the nerve controlling the voice box), wheezing, or repeated lung infections that keep coming back in the same area.
More general symptoms are also common: fatigue, weakness, loss of appetite, and unexplained weight loss. These tend to reflect the body’s overall response to the cancer rather than the tumor’s specific location.
Resectable vs. Unresectable Disease
One of the first and most important decisions in stage 3A treatment is whether the tumor can be surgically removed. This distinction, resectable versus unresectable, shapes the entire treatment plan.
A tumor is generally considered resectable when the lymph nodes involved on the same side of the chest are not bulky and the cancer hasn’t broken through the walls of those nodes into surrounding tissue. The patient also needs to be healthy enough to tolerate the operation, with adequate lung function and no serious heart disease that would make surgery too risky. If removing the cancer would require taking out an entire lung (a pneumonectomy) and the patient’s remaining lung can’t compensate, the tumor is considered unresectable even if it’s technically reachable.
Certain patterns of spread push a case toward unresectable. Invasion into vital structures like the heart, aorta, or esophagus usually rules out surgery, though there are exceptions: minimal invasion into the outer layer of the aorta or a small area of the left atrium near the pulmonary veins can sometimes be handled surgically. Fluid buildup around the lung or heart that contains cancer cells (a malignant effusion) also takes surgery off the table. And if lymph nodes on the opposite side of the chest are involved, that’s reclassified as more advanced disease and is not treated with surgery.
Treatment When Surgery Is Possible
For resectable stage 3A lung cancer, treatment almost always involves a combination of surgery and drug therapy, not surgery alone. The trend in recent years has been toward giving treatment both before and after surgery to improve outcomes.
Before surgery (neoadjuvant therapy), the standard approach now frequently includes immunotherapy combined with platinum-based chemotherapy. In a major clinical trial, patients who received an immunotherapy drug alongside chemotherapy for three cycles before surgery had dramatically better results than those who received chemotherapy alone. About 24% of patients in the immunotherapy group had no detectable cancer left in their surgical specimen, compared to just 2.2% in the chemotherapy-only group. Patients with stage 3A disease specifically saw greater benefit from this approach than those with earlier-stage cancers. The combination did not increase side effects or make surgery more difficult to perform.
After surgery, additional treatment (adjuvant therapy) may include more chemotherapy, immunotherapy, or targeted therapy if the tumor carries specific genetic changes. Some tumors have mutations that make them vulnerable to targeted drugs, particularly changes in genes called EGFR or ALK. Testing for these mutations is a routine part of the workup.
Treatment When Surgery Is Not Possible
For unresectable stage 3A lung cancer, the backbone of treatment is chemoradiation: chemotherapy and radiation therapy given at the same time. Concurrent treatment, where both are delivered during the same period rather than one after the other, offers the greatest survival benefit, though it also comes with more side effects like inflammation of the esophagus and fatigue.
If the cancer does not progress after chemoradiation, the current standard of care is consolidation immunotherapy with durvalumab, given for up to one year. This approach produced substantial improvements in survival for patients whose tumors express a protein called PD-L1 at levels of 1% or higher. Durvalumab works by blocking a signal that cancer cells use to hide from the immune system, essentially removing the tumor’s camouflage so the body’s own defenses can attack it.
This two-step approach, chemoradiation followed by immunotherapy, has become the defining treatment advance for unresectable stage 3 lung cancer in the past several years and is now considered standard at most cancer centers.
What Affects Individual Outlook
The 40% five-year survival figure for regional lung cancer is a population-level average that blends together many different situations. Several factors shift a person’s individual prognosis significantly. Smaller tumors with limited lymph node involvement do better than large tumors invading multiple structures. Tumors that respond to neoadjuvant therapy, especially those that show a complete pathological response (no cancer found in the surgical specimen), carry a much more favorable outlook. Patients who are healthy enough for surgery generally do better than those who are not.
Tumor biology matters too. Cancers with targetable mutations like EGFR or ALK rearrangements can be treated with highly effective targeted drugs, which can extend survival well beyond the averages. Tumors with high PD-L1 expression tend to respond better to immunotherapy. These molecular details, determined through biopsy and genetic testing, are just as important as the stage number itself in predicting how the disease will behave and which treatments will work best.
Stage 3A is a diagnosis with real complexity, and treatment plans are highly individualized. A multidisciplinary team, typically including a thoracic surgeon, medical oncologist, and radiation oncologist, reviews each case together to map out the best sequence of therapies.